News Biogen races into phase 3 with Spinraza follow-up Biogen is looking to the future of its spinal muscular atrophy (SMA) business, taking a candidate offering once-yearly dosing into phase 3.
News Biogen bids to extend use of Skyclarys to younger patients Biogen has started a new phase 3 trial that aims to extend the use of its Friedreich's ataxia drug Skyclarys to patients as young as two.
News After rebuffing Biogen, Sage pairs off with Supernus Sage Therapeutics has agreed to be acquired by Supernus Pharma in a deal valued at around $571 million.
News Data at EULAR back Biogen, UCB's first-in-class lupus drug Hopes rise for a new treatment option for people living with lupus, after UCB and Biogen reveal phase 3 data with their anti-CD40L antibody DZP.
News After delay, Alzheimer's drug Leqembi gets green light in EU The EU has approved Eisai and Biogen's Leqembi for a subset of patients with early-stage Alzheimer's disease, more than two years after it was filed.
News Gantenerumab 'shows sign of preventing Alzheimer's dementia' A study has suggested early targeting of amyloid in the brains of people with inherited Alzheimer's can delay symptoms, but not all are convinced.
News Just how radical is the FDA's complete response letter move? The FDA says publishing complete response letters for medicines is an act of "radical transparency," but it is not as revolutionary as it seems.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
